Merck and Endocyte's ovarian cancer drug fails in trial

Fri May 2, 2014 8:35am EDT

Related Topics

(Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.

The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.

An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.

(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Pictures